Buscar
Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
DMIIRAñadir a la lista de seguimiento
0.100USD
+0.020+25.00%
Cierre 05/15, 16:00（ET）Cotizaciones retrasadas 15 min
638.91MCap. mercado
--P/E TTM
Más Datos de Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 Compañía
Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.
Información de Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
Símbolo de cotizaciónDMIIR
Nombre de la empresaDrugs Made In America Acquisition II Corp
Fecha de salida a bolsaSep 25, 2025
Director ejecutivoStockwell (Lynn)
Número de empleados- -
Tipo de seguridadRight
Fin del año fiscal- -
Dirección1 East Broward Boulevard
CiudadFT LAUDERDALE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33301
Teléfono19548703099
Sitio Web
Símbolo de cotizaciónDMIIR
Fecha de salida a bolsaSep 25, 2025
Director ejecutivoStockwell (Lynn)
Ejecutivos de Drugs Made In America Acquisition II Rights Exp 16 Sep 2030
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 7 de may
Actualizado: jue., 7 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Otro
100.00%
Accionistas
Accionistas
Proporción
Otro
100.00%
Tipos de accionistas
Accionistas
Proporción
Otro
100.00%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
49
32.65M
0.00%
+30.29M
2025Q4
3
958.51K
0.00%
+958.51K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Magnetar Capital Partners LP
2.70M
0%
+2.70M
--
Dec 31, 2025
First Trust Capital Management L.P.
2.07M
0%
+2.07M
--
Dec 31, 2025
Hudson Bay Capital Management LP
1.97M
0%
+1.97M
--
Dec 31, 2025
Glazer Capital, LLC
1.90M
0%
+1.90M
--
Dec 31, 2025
OMERS Administration Corporation
1.00M
0%
+1.00M
--
Dec 31, 2025
Context Capital Management LLC
750.00K
0%
+750.00K
--
Dec 31, 2025
PICTON Investments
875.00K
0%
+875.00K
--
Dec 31, 2025
TD Securities, Inc.
1.63M
0%
+1.63M
--
Dec 31, 2025
Tenor Capital Management Co., L.P.
1.50M
0%
+1.50M
--
Dec 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
